Effect of rituximab on malignancy risk in patients with ANCA-Associated vasculitis

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 1064-1069

  Van Daalen, Emma E ^a   Rizzo, Raffaella ^b,c   Kronbichler, Andreas ^c,d   Wolterbeek, Ron ^a   Bruijn, Jan A ^a   Jayne, David R ^c   Bajema, Ingeborg M ^a   Rahmattulla, Chinar ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cyclophosphamide; DMARDs (biologic); Outcomes research; Systemic vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; STANDARDIZED INCIDENCE RATIO; TERTIARY HEALTH CARE; TREATMENT DURATION; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOSE RESPONSE; INCIDENCE; MIDDLE AGED; NEOPLASMS; SKIN NEOPLASMS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIRHEUMATIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RITUXIMAB; SKIN NEOPLASMS;

EID: 85006049537     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209925     Document Type: Article

References (39)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
2. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53.
3. Flossmann O, Berden A, de Groot K, et al. Long-Term patient survival in ANCA-Associated vasculitis. Ann Rheum Dis 2011;70:488-94.
4. Eriksson P, Jacobsson L, Lindell A, et al. Improved outcome in Wegeners granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009;265:496-506.
5. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
6. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegeners granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
7. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegeners granulomatosis. Int J Cancer 2002;100:82-5.
8. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegeners granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
9. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-Associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011;70:1415-21.
10. Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-Treated patients with granulomatosis with polyangiitis (Wegeners): long-Term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011;63:2495-503.
11. Rahmattulla C, Berden AE, Wakker SC, et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-Associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheum 2015;67:3270-8.
12. Faurschou M, Mellemkjaer L, Voss A, et al. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 2015;54:1345-50.
13. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegeners granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307-11.
14. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
15. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-Associated vasculitis: A randomized trial. Ann Intern Med 2009;150:670-80.
16. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegeners granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44: 2836-40.
17. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegeners granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
18. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178-82.
19. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-Associated vasculitis. N Engl J Med 2013;369:417-27.
20. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010;363:221-32.
21. Karassa FB. Rituximab or cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med 2010;363:2073; author reply 73-4.
22. Falk RJ, Jennette JC. Rituximab in ANCA-Associated disease. N Engl J Med 2010;363:285-6.
23. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-Associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
24. Cancer Statistics: Registration Series MB1 (Accessed October 2015) http://www.ons. gov.uk/ons/taxonomy/index.html?nscl=Cancer+Registrations
25. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990;131:373-5.
26. Thomsen JL, Parner ET. Methods for analysing recurrent events in health care data. Examples from admissions in Ebeltoft Health Promotion Project. Fam Pract 2006;23:407-13.
27. Sun J, Ono Y, Takeuchi Y. A simple method for calculating the exact confidence interval of the SMR with a SAS function. J Occup Health 1996;38:196-7.
28. Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7.
29. Schioppa T, Moore R, Thompson RG, et al. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci USA 2011;108:10662-7.
30. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol 2013;34:169-73.
31. Cho SF, Wu WH, Yang YH, et al. Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: A nationwide population-based study. Anticancer Res 2015;35:1809-14.
32. Xu Y, Wang H, Zhou S, et al. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2013;54:1396-404.
33. van den Reek JM, van Lömig PP, Janssen M, et al. Increased incidence of squamous cell carcinoma of the skin after long-Term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol 2014;28:27-33.
34. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
35. Pedersen EG, Pottegard A, Hallas J, et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol 2014;21:454-8.
36. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:119-30.
37. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study. J Gastroenterol Hepatol 2012;27:385-9.
38. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: Advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:263-79; quiz 80.
39. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-17.